Cantor Fitzgerald Analysts Lower Earnings Estimates for FATE

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Cantor Fitzgerald reduced their FY2026 earnings per share (EPS) estimates for Fate Therapeutics in a report issued on Wednesday, August 20th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earnings of ($0.93) per share for the year, down from their prior forecast of ($0.73). The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Other equities analysts have also recently issued research reports about the company. Wells Fargo & Company cut their price objective on Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a research report on Wednesday, August 13th. Barclays cut their price objective on Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a research report on Wednesday, May 14th. Wall Street Zen raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a report on Thursday, June 12th. Finally, Robert W. Baird cut their price target on Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating for the company in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $3.30.

Fate Therapeutics Stock Performance

NASDAQ FATE opened at $1.15 on Friday. Fate Therapeutics has a twelve month low of $0.6611 and a twelve month high of $4.20. The stock has a market capitalization of $132.63 million, a PE ratio of -0.79 and a beta of 2.24. The stock has a 50-day simple moving average of $1.13 and a 200 day simple moving average of $1.13.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%.The company had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $1.16 million.

Institutional Investors Weigh In On Fate Therapeutics

Several large investors have recently modified their holdings of FATE. LPL Financial LLC bought a new stake in shares of Fate Therapeutics in the 4th quarter valued at approximately $121,000. Wells Fargo & Company MN grew its stake in shares of Fate Therapeutics by 56.3% in the 4th quarter. Wells Fargo & Company MN now owns 92,395 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 33,284 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Fate Therapeutics by 42.9% in the 4th quarter. Russell Investments Group Ltd. now owns 89,823 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 26,953 shares during the period. Renaissance Technologies LLC grew its stake in shares of Fate Therapeutics by 4.4% in the 4th quarter. Renaissance Technologies LLC now owns 378,619 shares of the biopharmaceutical company’s stock valued at $625,000 after purchasing an additional 16,000 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Fate Therapeutics in the 4th quarter valued at approximately $846,000. 97.54% of the stock is currently owned by institutional investors.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.